Fig. 6

NHE1 blockade enhanced anti-tumor immunity in glioma model. a GSEA indicates the diversity of immune phenotype in the case with different NHE1 expression in CGGA dataset. q, adjust p value. b Regression correlation analysis of NHE1 mRNA expression and CD8 T cells/Cytotoxic lymphocytes metagene score in CGGA dataset. c Representative flow-cytometry plots of CD4 T cells stained for CD25 and FoxP3 in unstained (fluorescence minus CD25 and FoxP3), FMO (fluorescence minus FoxP3) control, Veh, and HOE. Data are means ± SD from five independent experiments. ns, no significance; *, p < 0.05. d Infiltration of CD8 T cell in SB28-GFP tumor borders. Data are means ± SD from four independent experiments. *, p < 0.05. e Flow cytometric plots of CD4⁺ and CD8⁺ T cells stained for IFNγ and PD-1 are shown in Additional file 1: Figure S9. Data are means ± SD from five independent experiments. ns, no significance; *, p < 0.05. f Glioma cells were injected into the right striatum of C57BL6/J mice. Starting 5 d.p.i., mice received either vehicle PBS-DMSO (10 ml/kg/day, i.p.) or HOE treatments (0.5 mg/kg/day, i.p.) for 5 consecutive days. Mice received either isotype antibody (10 ml/kg/day, i.p.) or anti-PD-1 (10 mg/kg/day, i.p.) at 8, 10, and 12 d.p.i. g, h Kaplan-Meier survival curve of SB28-GFP tumor-bearing mice and GL26 tumor-bearing mice, respectively. Each group, N = 5–8. *, p < 0.05; **, p < 0.01; ***, p < 0.001